
|Articles|January 3, 2014
Big Pharma's Second Life
Drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle.
Advertisement
Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at CBI's Sponsor/CRO Systems & Business Process Integration conference in The Triangle.
Check out the
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
A Shot in the Arm to Traditional Vaccine Trial Strategy
5



